Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (221-230 of 315) with videos related to

Pageof 32
Sort By:
BMJ Open|November 28, 2020
International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationaleKatrina Abuabara, Jonathan I Silverberg, Eric L Simpson, et al.
American Journal of Clinical Dermatology|May 2, 2024
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 StudiesLawrence F Eichenfield, Eric L Simpson, Kim Papp, et al.
JAMA Dermatology|August 4, 2021
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialAndrew Blauvelt, Henrique D Teixeira, Eric L Simpson, et al.
JAMA Dermatology|May 22, 2024
Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus StatementMichael E Jacobson, Yael A Leshem, Christian Apfelbacher, et al.
Dermatology and Therapy|September 23, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?Eric L Simpson, Jonathan I Silverberg, Bob Geng, et al.
The Journal of Dermatological Treatment|May 11, 2026
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trialsEric L Simpson, Vimal H Prajapati, Christopher G Bunick, et al.
American Journal of Clinical Dermatology|October 13, 2021
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|April 2, 2021
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With AbrocitinibEric L Simpson, Andreas Wollenberg, Robert Bissonnette, et al.
The British Journal of Dermatology|September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trialsEric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.
American Journal of Clinical Dermatology|August 18, 2021
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Pageof 32

Showing results (221-230 of 315) with videos related to

Sort By:
Pageof 32
BMJ Open|November 28, 2020
International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationaleKatrina Abuabara, Jonathan I Silverberg, Eric L Simpson, et al.
American Journal of Clinical Dermatology|May 2, 2024
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 StudiesLawrence F Eichenfield, Eric L Simpson, Kim Papp, et al.
JAMA Dermatology|August 4, 2021
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialAndrew Blauvelt, Henrique D Teixeira, Eric L Simpson, et al.
JAMA Dermatology|May 22, 2024
Measuring Signs of Atopic Dermatitis in Clinical Practice: A HOME-CP Consensus StatementMichael E Jacobson, Yael A Leshem, Christian Apfelbacher, et al.
Dermatology and Therapy|September 23, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?Eric L Simpson, Jonathan I Silverberg, Bob Geng, et al.
The Journal of Dermatological Treatment|May 11, 2026
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trialsEric L Simpson, Vimal H Prajapati, Christopher G Bunick, et al.
American Journal of Clinical Dermatology|October 13, 2021
Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|April 2, 2021
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With AbrocitinibEric L Simpson, Andreas Wollenberg, Robert Bissonnette, et al.
The British Journal of Dermatology|September 9, 2022
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trialsEric L Simpson, Joseph F Merola, Jonathan I Silverberg, et al.
American Journal of Clinical Dermatology|August 18, 2021
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Pageof 32